The Future of Single-Use Components in Biopharmaceutical Production

July
,
2019

Single-use equipment has become ubiquitous in the biopharmaceutical industry, but further development in four key areas is needed to continue progress in this field.

The biopharmaceutical industry has employed single-use systems consisting of bags, tubing, filters, and other connecting elements (Figure 1) for more than 25 years. Virtually all processes have at least one aspect that can benefit from the convenience of disposable, presterilized components. Many industries have rapidly adopted single-use technologies because they offer quick turnaround times, low capital costs, and significantly lower validation costs.

images

Figure 1. Single-use equipment can include presterilized, disposable bags, tubing, fittings, and connectors. Bioreactor volumes up to 2,000 L are also available for completely single-use cell culture processes.

New biopharmaceutical facilities are able to benefit from a single-use system upon start-up, thus avoiding the costly buildout of a fully stainless steel reusable plant. The adoption of single-use equipment and the prevalence of contract manufacturing organizations (CMOs) can reduce the timescales and up-front investment costs required to develop pharmaceuticals.

As single-use technologies become more commonplace, users are demanding advances and improvements in these technologies and their associated processing techniques. The BioPhorum Operations Group (BPOG) has published a set of explicit requests and roadmaps for advances in biopharmaceutical production, some of which provide feedback on single-use technologies.

Users and equipment manufacturers must work together to improve single-use systems as the industry shifts away from reusable equipment. This article addresses four areas where development is needed, and discusses how together biopharmaceutical companies and equipment manufacturers will be responsible for driving change. These four areas for potential development are:

  • understanding and reporting of biocompatibility
  • improving integrity assurance for single-use systems
  • integrating single-use measurement and automation to support process analytical technology (PAT) efforts
  • developing a resilient global supply network.
Author Bios: 

Matthew Olsen

Matthew Olsen works at Sartorius Stedim Biotech (Email: Matthew.Olsen@Sartorius-Stedim.com), where he currently focuses on single-use mixing and integrity testing technologies. He has more than 15 years of experience with single-use technologies in the biopharmaceutical industry, including as a member of the development team for the Celsius Controlled Freeze-Thaw System, which was the first single-use freeze-and-thaw platform developed for the pharmaceutical industry. Olsen holds a BS in chemical engineering from Rensselaer...Read more

Would you like to access the complete CEP Article?

No problem. You just have to complete the following steps.

You have completed 0 of 2 steps.

  1. Log in

    You must be logged in to view this content. Log in now.

  2. AIChE Membership

    You must be an AIChE member to view this article. Join now.

Copyright Permissions: 

Would you like to reuse content from CEP Magazine or purchase an article reprint? Learn more about Reprints and Permissions